Casirivimab/Imdevimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.

**Synonyms:** - Anti-COVID Cocktail REGN-COV2 - Anti-Spike SARS-CoV-2 Monoclonal Antibodies REGN-COV2 - Casirivimab Plus Imdevimab - Casirivimab and Imdevimab - Casirivimab+Imdevimab - Monoclonal antibodies against SARS-CoV-2: casirivimab/imdevimab - REGEN-COV - REGN COV2 - REGN-COV2 - REGN10933 Plus REGN10987 - REGN10933+REGN10987 - REGN10933/REGN10987 - REGNCOV2 - SARS-CoV-2-specific Antibodies REGN10933 and REGN10987